VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Details
Serval ID
serval:BIB_E123EA0B584E
Type
Article: article from journal or magazin.
Publication sub-type
Editorial
Collection
Publications
Institution
Title
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Journal
Annals of Oncology
ISSN
0923-7534
Publication state
Published
Issued date
07/2021
Volume
32
Number
7
Pages
942-944
Language
english
Keywords
Oncology, Hematology
Web of science
Open Access
Yes
Create date
18/03/2022 19:10
Last modification date
11/11/2022 7:39